TACE联合三氧化二砷治疗原发性肝癌的临床研究

Clinical effect of transcatheter arterial chemoembolization combined with arsenic trioxide in the treatment of primary liver cancer

目的:探讨三氧化二砷(As2O3)联合经导管肝动脉化疗栓塞术(TACE)对中晚期原发性肝癌的治疗效果。方法:经病理、影像学诊断及AFP值证实的原发性肝癌符合筛选条件的患者共53例,28例和25例分别采用TACE联合As2O3和单纯TACE治疗,分别评价近期疗效、远期疗效、AFP变化、毒副反应和生活质量。结果:试验组与对照组疾病控制率分别为64.3%和52.0%,P=0.365。两组1年生存率分别为67.86%和40.00%,P=0.042,1年半生存率分别为57.14%和28.00%,P=0.033。AFP变化分别为28.57%和24.00%,P=0.706;两组毒副反应基本可以耐受,生活质量有一定改善。结论:As2O3联合TACE治疗原发性肝癌能提高一年及一年半生存率,不良反应较小。

Objective：To evaluate the treatment effect of arsenic trioxide（As2O3） combined with transcatheter arterial chemoembolization （TACE） for advanced primary liver cancer（PLC）.Methods：A total of 53 PLC cases,28 patients were treated with TACE combined with As2O3 and 25 patients with TACE alone.Resuts：The disease control rate of the test group and the control group were 64.3% and 52.0%,P =0.365.1-year survival rates were 67.86% and 40.00%,P=0.042.1 and a half years survival rates were 57.14% and 28.00%,P=0.033.AFP change of 28.57% and 24.00%,P =0.706.Side effects can be tolerated.Conclusion：As2O3 combined with TACE treatment of primary liver cancer can improve 1-year survival rate with less adverse reactions.